Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01892202
Expanded Access Status : No longer available (Investigators lost interest in conducting the trail due to unexplained reasons)
First Posted : July 4, 2013
Last Update Posted : October 27, 2016
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This multicenter observational study will evaluate the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic kidney disease not on dialysis in routine clinical practice. Eligible patients treated with Mircera for chronic renal anemia according to the standard of care and in line with the current local label will be followed for 6 months.

Condition or disease Intervention/treatment
Anemia Other: Cohort

Layout table for study information
Study Type : Expanded Access
Official Title: Efficacy of C.E.R.A for Correction of Anemia and Maintenance of the Hb Levels in CKD Patients in Stage III - IV , Not on Dialysis , Treated According to Routine Clinical Practice
Study Start Date : February 2011
Estimated Primary Completion Date : February 2011
Estimated Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients, 18 to 65 years of age inclusive
  • Patients with chronic kidney disease Stage III-IV not on dialysis
  • Hb < 10 g/dL (for correction of anemia) or Hb 10-12 g/dL and receiving any other ESA (for maintenance of Hb levels)
  • Adequate iron status as judged by the treating physician

Exclusion Criteria:

  • Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication
  • Significant acute or chronic bleeding
  • Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)
  • Active malignant disease during the last five years (except non-melanoma skin cancer)
  • Uncontrolled or symptomatic secondary hyperparathyroidism
  • Epileptic seizure during the last 6 months
  • Poorly controlled hypertension (sitting blood pressure > 170/100 mmHG)
  • Myocardial infarction or stroke, or severe or unstable CAD
  • Severe liver disease during the previous 6 months
  • Congestive heart failure NYHA Class III-IV
  • Diagnosis or suspicion of pure red cell aplasia (PRCA)
  • Planned elective surgery during the study period (except cataract surgery and vascular access surgery)
  • Transfusion of red blood cells during the previous 2 months
  • Pregnant women
  • Any contra-indications to Mircera

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01892202


Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01892202    
Other Study ID Numbers: ML25750
First Posted: July 4, 2013    Key Record Dates
Last Update Posted: October 27, 2016
Last Verified: October 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia
Hematologic Diseases